Investigating a new treatment for heart disease caused by thickened heart muscle.
Official title: C-type natriuretic peptide in hypertrophic cardiomyopathy
Funded at Vanderbilt University Medical Center · NIH-11000261 · Data updated 2026-11-12
This study is looking at a new treatment using a special version of a heart-related protein called CNP to see if it can help people with hypertrophic cardiomyopathy (HCM) by reducing heart muscle thickening and improving their condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | December 15, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $130,518 |
| NIH project number | 5K99HL171847-02 |
| Project ID | NIH-11000261 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those experiencing symptoms related to cardiac fibrosis.
✕Less likely to help
Patients without hypertrophic cardiomyopathy or those whose condition is not related to cardiac fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding how C-type natriuretic peptide (CNP) can be used to treat hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. The study aims to explore the potential of a CNP analog called C53, which may help reduce fibrosis, a key factor that worsens HCM. By using innovative methods to deliver C53 effectively, the researchers hope to determine if it can prevent or reverse fibrosis in patients with HCM. This could lead to new therapeutic options for individuals suffering from this condition.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that effectively reduces heart muscle fibrosis in patients with hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting natriuretic peptides, suggesting potential for success in this novel application.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Armstrong, David William John — Vanderbilt University Medical Center
- Study coordinator: Armstrong, David William John
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.